REGN · Regeneron Pharmaceuticals, Inc. · Earnings Call Transcripts & Audio
$759.00
+8.49 (+1.13%)
At close · Sep 30
Return incl. dividend (before tax)
Market Cap
$81.13B
Shares
102.95M
Volume · Sep 30
873.34K
Avg daily vol (3M)
755K
Regeneron Pharmaceuticals, Inc. Earnings Call Transcripts
Quarterly earnings calls for Regeneron Pharmaceuticals, Inc. (REGN), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼31%
$3.41B
$1.20B
'22 Q4
23-02-03
▲6.6%
$3.16B
$817.80M
'23 Q1
23-04-10
▲10.5%
$3.16B
$968.40M
'23 Q2
23-08-03
▲14.5%
$3.36B
$1.01B
'23 Q3
23-10-05
▲0.6%
$3.43B
$1.16B
'23 Q4
24-01-08
▼0.5%
$3.15B
$722.00M
'24 Q1
24-05-02
▲12.3%
$3.55B
$1.43B
'24 Q2
24-08-01
▲10.6%
$3.72B
$1.34B
'24 Q3
24-10-31
▲10.3%
$3.79B
$917.70M
'24 Q4
25-01-13
▼3.7%
$3.03B
$808.70M
'25 Q1
25-04-29
▲3.6%
$3.68B
$1.39B
'25 Q2
25-08-01
▲0.9%
$3.75B
$1.46B
'25 Q3
25-10-28
▲2.5%
$3.88B
$844.60M
'25 Q4
26-01-30
▲19%
$3.61B
$727.20M
'26 Q1
26-04-29
LATEST
▲16.7%
$4.29B
$1.30B
'26 Q2
26-07-30
Earnings call
FY26 · Q3
2026-10-30
Regeneron Pharmaceuticals, Inc. (REGN) Q3 2026 Earnings Call
Scheduled
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-14
Regeneron Pharmaceuticals, Inc. (REGN) September 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-09
Regeneron Pharmaceuticals, Inc. (REGN) September 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-07-30
Regeneron Pharmaceuticals, Inc. (REGN) Q2 2026 Earnings Call Transcript
Confident tone
Dupixent growth and Sanofi collaboration
EYLEA HD franchise dynamics
Libtayo oncology momentum
Revenue
$4.29B
▲ 16.7% YoY Diluted EPS
$12.23
▼ 4.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Annual General Meeting
Investor event
2026-06-12
Regeneron Pharmaceuticals, Inc. (REGN) June 2026 Annual General Meeting Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-08
Regeneron Pharmaceuticals, Inc. (REGN) June 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-04-29
Regeneron Pharmaceuticals, Inc. (REGN) Q1 2026 Earnings Call Transcript
Confident tone
DUPIXENT commercial performance
EYLEA HD growth and manufacturing
Pipeline breadth and R&D productivity
Revenue
$3.61B
▲ 19% YoY Diluted EPS
$6.75
▼ 7.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-01-30
Regeneron Pharmaceuticals, Inc. (REGN) Q4 2025 Earnings Call Transcript
Confident tone
Dupixent growth and indication expansion
Factor XI antibody anticoagulant program
Libtayo oncology momentum
Revenue
$3.88B*
▲ 2.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-28
Regeneron Pharmaceuticals, Inc. (REGN) Q3 2025 Earnings Call Transcript
Confident tone
Dupixent growth and label expansion
Pipeline progress and pivotal data
EYLEA HD performance and headwinds
Revenue
$3.75B
▲ 0.9% YoY Diluted EPS
$13.62
▲ 18% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-01
Regeneron Pharmaceuticals, Inc. (REGN) Q2 2025 Earnings Call Transcript
Positive tone
Dupixent growth and label expansion
EYLEA legacy decline
Libtayo franchise expansion
Revenue
$3.68B
▲ 3.6% YoY Diluted EPS
$12.81
▲ 3.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-04-29
Regeneron Pharmaceuticals, Inc. (REGN) Q1 2025 Earnings Call Transcript
Balanced tone
Dupixent growth and COPD launch
EYLEA franchise performance
Pipeline progress and regulatory milestones
Revenue
$3.03B
▼ 3.7% YoY Diluted EPS
$7.27
▲ 15.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-01-13
Regeneron Pharmaceuticals, Inc. (REGN) Q4 2024 Earnings Call Transcript
Confident tone
EYLEA HD label expansion and competitive pressure
Dupixent franchise and growth
LAG-3/PD-1 combo in melanoma and lung
Revenue
$3.79B*
▲ 10.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-31
Regeneron Pharmaceuticals, Inc. (REGN) Q3 2024 Earnings Call Transcript
Confident tone
EYLEA HD commercial performance and durability
Dupixent growth and COPD launch
Pipeline catalysts and readouts
Revenue
$3.72B
▲ 10.6% YoY Diluted EPS
$11.54
▲ 29.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Regeneron Pharmaceuticals, Inc. (REGN) Q2 2024 Earnings Call Transcript
Confident tone
EYLEA HD launch
DUPIXENT growth and COPD expansion
Linvoseltamab / BCMA regulatory delay
Revenue
$3.55B
▲ 12.3% YoY Diluted EPS
$12.41
▲ 46% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-02
Regeneron Pharmaceuticals, Inc. (REGN) Q1 2024 Earnings Call Transcript
Confident tone
Dupixent COPD regulatory review
Severe allergy combination approach
EYLEA HD launch momentum
Revenue
$3.15B
▼ 0.5% YoY Diluted EPS
$6.27
▼ 12.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-01-08
Regeneron Pharmaceuticals, Inc. (REGN) Q4 2023 Earnings Call Transcript
Confident tone
EYLEA HD Launch and Execution
Dupixent Growth and COPD Expansion
Oncology Pipeline and Launches
Revenue
$3.43B*
▲ 0.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-10-05
Regeneron Pharmaceuticals, Inc. (REGN) Q3 2023 Earnings Call Transcript
Revenue
$3.36B
▲ 14.5% YoY Diluted EPS
$8.89
▼ 23.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Regeneron Pharmaceuticals, Inc. (REGN) Q2 2023 Earnings Call Transcript
Revenue
$3.16B
▲ 10.5% YoY Diluted EPS
$8.50
▲ 13.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-04-10
Regeneron Pharmaceuticals, Inc. (REGN) Q1 2023 Earnings Call Transcript
Revenue
$3.16B
▲ 6.6% YoY Diluted EPS
$7.17
▼ 16.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-03
Regeneron Pharmaceuticals, Inc. (REGN) Q4 2022 Earnings Call Transcript
Revenue
$3.41B*
▼ 31% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Regeneron Pharmaceuticals, Inc. (REGN) Q3 2022 Earnings Call Transcript
Revenue
$2.94B
▼ 15% YoY Diluted EPS
$11.66
▼ 18.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-03
Regeneron Pharmaceuticals, Inc. (REGN) Q2 2022 Earnings Call Transcript
Revenue
$2.86B
▼ 44.4% YoY Diluted EPS
$7.47
▼ 73.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
Regeneron Pharmaceuticals, Inc. (REGN) Q1 2022 Earnings Call Transcript
Revenue
$2.97B
▲ 17.3% YoY Diluted EPS
$8.61
▼ 14.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-04
Regeneron Pharmaceuticals, Inc. (REGN) Q4 2021 Earnings Call Transcript
Revenue
$4.95B*
▲ 104.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Regeneron Pharmaceuticals, Inc. (REGN) Q3 2021 Earnings Call Transcript
Revenue
$3.45B
▲ 50.5% YoY Diluted EPS
$14.33
▲ 93.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Regeneron Pharmaceuticals, Inc. (REGN) Q2 2021 Earnings Call Transcript
Revenue
$5.14B
▲ 163.2% YoY Diluted EPS
$27.97
▲ 267.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Regeneron Pharmaceuticals, Inc. (REGN) Q1 2021 Earnings Call Transcript
Revenue
$2.53B
▲ 38.3% YoY Diluted EPS
$10.09
▲ 85.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-01-11
Regeneron Pharmaceuticals, Inc. (REGN) Q4 2020 Earnings Call Transcript
Revenue
$2.42B
▲ 30% YoY Diluted EPS
$10.24
▲ 47.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Regeneron Pharmaceuticals, Inc. (REGN) Q3 2020 Earnings Call Transcript
Revenue
$2.29B
▲ 31.6% YoY Diluted EPS
$7.39
▲ 26.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-05
Regeneron Pharmaceuticals, Inc. (REGN) Q2 2020 Earnings Call Transcript
Revenue
$1.95B
▲ 23.7% YoY Diluted EPS
$7.61
▲ 353% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-05
Regeneron Pharmaceuticals, Inc. (REGN) Q1 2020 Earnings Call Transcript
Revenue
$1.83B
▲ 33.2% YoY Diluted EPS
$5.43
▲ 36.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Showing 1–31 of 31 earnings calls
Key facts
CIK
872589
CUSIP
75886F107
13F (30d)
24 filings
20 filers
Visit website
Investor relations